ProCE Banner Activity


State-of-the-Art Biomarker Testing in Gastrointestinal Cancer: Guidance for Oncologists and Pathologists

In this on-demand webcast from a live symposium, an expert oncologist and pathologist discuss the latest data on using biomarkers to guide treatment of GI cancers.

ABIM MOC : maximum of 1.25 Medical Knowledge MOC point(s)

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: April 18, 2022

Expiration: April 17, 2023

No longer available for credit.



E. Scott Kopetz

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Dipen Maru

Dipen Maru, MD

Department of Pathology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Pfizer, Inc.

Seagen Inc.


American Society for Clinical Pathology

ProCE Banner

Target Audience

This program is intended for oncologists and pathologists who care for patients with gastrointestinal cancers.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply the available data and expert recommendations to determine which biomarkers should be assessed in patients with GI malignancies
  • Implement best practices for molecular testing in GI cancers, including the use of tissue-based biomarker testing for evaluation of BRAF V600E, HER2/HER3, BRCA1/2, FGFR2, IDH1, and tumor agnostic markers
  • Plan therapeutic strategies for patients with GI malignancies based on predictive biomarker assessment to improve duration and quality of life
  • Evaluate the clinical validity, utility, and differences among single biomarker companion diagnostics and available comprehensive genomic testing platforms using next-generation sequencing
  • Appraise ongoing clinical trials for novel biomarker-driven treatment strategies in GI malignancies for patient counsel and potential enrollment


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty Disclosure

Primary Author

E. Scott Kopetz, MD, PhD, FACP

Assistant Professor
Department of Gastrointestinal Medical Oncology
The University of Texas M. D. Anderson Cancer Center
Houston, Texas

Scott Kopetz, MD, PhD, FACP, has disclosed that he has received consulting fees from AbbVie, Amal, AstraZeneca/MedImmune, Bayer, Bicara, Boehringer Ingelheim, Boston Biomedical, Carina, Daiichi Sankyo, EMD Serono, Endeavor, Flame, Frontier, Genentech, Genomic Health, Gilead, GlaxoSmithKline, HalioDx, Holy Stone, Iylon, Inivata, Ipsen, Jacobio, Jazz, Johnson & Johnson/Janssen, Lilly, Lutris, Merck, Mirati, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx, Repare, Replimune, Servier, Taiho, and Xilis; has received funds for research support from Amgen, Array, Biocartis, Daiichi Sankyo, EMD Serono, Genentech/Roche, Guardant, Lilly, MedImmune, Novartis, and Sanofi; and has stock/ownership interest in Frontier, Iylon, Lutris, and MolecularMatch.

Dipen Maru, MD

Department of Pathology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Dipen Maru, MD, has disclosed that he has received funds for research support from AstraZeneca/Medimmune, Daiichi Sankyo, and EMD Serono.

Staff Disclosure


Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has disclosed he owned publicly traded stocks/stock options in AstraZeneca.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.

Instructions for Credit


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 18, 2022, through April 17, 2023:

1. Register online at
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


The goal of this educational curriculum is to improve the knowledge, competence, and performance of learners to optimally diagnose gastrointestinal cancers that have a biomarker predictive for treatment benefit and plan individualized treatment based on current and emerging therapeutic strategies for patients with gastrointestinal cancers.